Prospero相关同源异形盒蛋白1在宫颈癌组织中的表达及其临床意义-东南大学学报医学版

Prospero相关同源异形盒蛋白1在宫颈癌组织中的表达及其临床意义

单位：1. 铁岭市中心医院妇产科, 辽宁铁岭 112000;
2. 中国医科大学附属盛京医院滑翔院区妇科, 辽宁沈阳 110022

分类号：R737.33

出版年·卷·期（页码）：2021·40·第三期（376-380）

摘要：

目的：探讨Prospero相关同源异形盒蛋白1（PROX1）在宫颈癌组织中的表达及其临床意义。方法：用免疫组化染色法检测81例宫颈癌组织及其配对的癌旁组织中PROX1的表达水平。根据免疫组化染色结果将患者分为高表达组和低表达组，比较两组临床病理特征及生存预后。结果：癌组织中PROX1表达率为69.14%（56/81），明显高于癌旁组织表达率11.11%（9/81），差异有统计学意义（P<0.001）。高表达组组织低分化、深浸润和淋巴结转移率均高于低表达组（均P<0.05）。肿瘤低分化、浸润较深、淋巴结转移、未辅助化疗、PROX1高表达是宫颈癌患者不良生存预后的独立影响因素（均P<0.05）。高表达组5年生存率为40.74%，明显低于低表达组的71.73%（P<0.05）。结论：PROX1与宫颈癌的发生及发展有关，并且对生存预后的评估有一定价值。

Objective: To investigate the expression and clinical significance of Prospero-related homeobox 1 (PROX1) in cervical cancer. Methods: Immunohistochemical staining was used to detect the expression of PROX1 in 81 cervical cancer tissues and adjacent tissues. Patients were divided into PROX1 high expression group and PROX1 low expression group, the differences of clinical-pathological characteristics and survival prognosis were compared between the two groups according to the staining performance. Results: The ratio of PROX1 expressed in cancer tissues was 69.14(56/81), which was significantly higher than adjacent tissues 11.11%(9/81)(P<0.05). The poor differentiation, deep invasion and metastatic lymph node ratio of PROX1 high expression group were significantly higher than those of PROX1 low expression group(P<0.05), poor differentiation, deep invasion, lymph node metastasis, no adjuvant chemotherapy and higher expression of PROX1 were the independent influence factors in the process of cervical cancer(P<0.05). The 5-year survival rate of the PROX1 high expression group was 40.74%, which was lower than 71.73% of PROX1 low expression group(P<0.05). Conclusion: PROX1 is associated with cervical cancer oncogenesis and development, and PROX1 has a certain value to evaluate the outcomes of cervical cancer patients.

参考文献：

[1] 王宇, 宋淑芳, 刘凤.我国宫颈癌流行病学特征和发病高危因素的研究进展[J]. 中国妇幼保健, 2019, 34(5):1207-1209.
[2] 李雯君.Prox-1与淋巴管新生和肿瘤转移的关系[J]. 临床与病理杂志, 2010, 30(4):332-336.
[3] XU X, WAN X, WEI X.PROX1 promotes human glioblastoma cell proliferation and invasion via activation of the nuclear factor-κB signaling pathway[J]. Mol Med Rep, 2017, 15(2):963-968.
[4] RUDZIŃSKA M, MIKULA M, ARCZEWSKA K D.Transcription factor prospero homeobox 1(PROX1) as a potential angiogenic regulator of follicular thyroid cancer dissemination[J]. Int J Mol Sci, 2019, 20(22):5619-5628.
[5] 赵东丽, 梁宪斌, 王艳, 等. Prospero相关同源异形盒蛋白1在乳腺癌组织中的表达及与预后相关性分析[J]. 中国癌症杂志, 2019, 29(4):272-276.
[6] LIU Y, YE X, ZHANG J B, et al. PROX1 promotes hepatocellular carcinoma proliferation and sorafenib resistance by enhancing β-catenin expression and nuclear translocation[J]. Oncogene, 2015, 34(44):5524-5535.
[7] 郑小影, 郝云涛, 赵淑敏, 等. 宫颈癌中MST1蛋白的表达及临床意义[J]. 天津医药, 2017, 45(4):402-405.
[8] ZHANG B, CHEN X, LIN Y, et al. Occludin protein expression in human cervical cancer and its association with patient's clinical characteristics[J]. J Cancer Res Ther, 2018, 14(1):124-127.
[9] CANFELL K.Towards the global elimination of cervical cancer[J]. Papillomavirus Res, 2019, 8(12):100170.
[10] YU Z Y, WU L, ZHAO F K, et al. RNA-seq reveals transcriptome changes of the embryonic lens cells in PROX1 tissue specific knockout mice[J]. Eur Rev Med Pharmacol Sci, 2019, 23(18):7740-7748.
[11] GRAMOLELLI S, CHENG J, MARTINEZ-CORRAL I.PROX1 is a transcriptional regulator of MMP14[J]. Sci Rep, 2018, 8(1):318-322.
[12] HÖGSTRÖM J, HEINO S, KALLIO P, et al. Transcription factor PROX1 suppresses notch pathway activation via the nucleosome remodeling and deacetylase complex in colorectal cancer stem-like cells[J]. Cancer Res, 2018, 78(20):5820-5832.
[13] WANG D, LI Q, LI Y, et al. The role of MCM5 expression in cervical cancer:correlation with progression and prognosis[J]. Biomed Pharmacother, 2018, 98:165-172.
[14] 赵亚琼, 任琛琛, 杨立, 等. CK10和CK17在早期宫颈癌组织中的表达及其预测预后的价值[J]. 现代肿瘤医学, 2019, 27(11):120-126.
[15] 董仙萍.BMI-1、C-myc在宫颈癌组织中的表达及与患者预后的关系研究[J]. 标记免疫分析与临床, 2019, 26(6):1034-1039, 1062.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录